One third of all newly diagnosed cancers in men is prostate cancer, which accounts for 10% of cancer deaths. In 2008, an estimated 186,320 men were diagnosed with prostate cancer and approximately 28,660 died of the disease. The lifetime risk is 1 in 6 with a risk of dying of 1 in 30, and most men with prostate cancer die of other causes. Individuals with one first degree relative diagnosed with prostate cancer have twice the lifetime risk, whereas this increases to four times if two or more relatives are affected before the age of 70. It is estimated that 5% to 10% of all cases are hereditary, an area of intense research. The higher incidence in Western countries suggests the influence of environmental factors. High fat consumption is thought to increase the risk by two-to threefold. Ethnicity also plays an important role with a higher incidence of prostate cancer in African American men as compared to White men. 1 The role of screening remains controversial.
Although the management of prostate cancer appears complex and convoluted, the initial approach is relatively straightforward. Local disease is treated by either radical prostatectomy or radiation therapy with curative intent. Both, however, are associated with significant side effects 2 :
Side effects of radical prostatectomy
Side effects of radiation therapy
When the disease recurs, the treatment options often appear muddled. However, prostate cancer is very similar to breast cancer in that both these diseases are hormonally driven, that is, estrogen in breast cancer and androgens in prostate cancer. The treatment approach, therefore, is to block this stimulating hormone with a wide variety of agents. Since the 1940s, androgen blockade or ablation has been the mainstay of treatment of advanced prostate cancer. This can be achieved in a variety of ways such as Unfortunately, this androgen blockade, regardless of the mechanism, often leads to the following side effects 2 :
Castration (regardless of the method used to reduce testosterone levels) • Gynecomastia (49%-66%); • Breast pain (40%-72%); • Hot flashes (9%-13%).
Despite this myriad of hormonal therapies, the disease ultimately progresses. The next option for this hormone-refractory or castration-resistant metastatic prostate cancer is chemotherapy in the form of docetaxel, which has shown a modest improvement in survival. The overall median survival after chemotherapy is less than 2 years, but several newer treatment options for these patients have emerged. It had been generally assumed that progression after androgen deprivation therapy denoted hormone refractory disease; however, the evidence clearly suggest that these cancers remain hormone sensitive. Abiraterone acetate inhibits androgen synthesis and lowers testosterone levels to nearly detectable amounts but does not affect androgen receptor signaling. Fizazi et al 3 recently reported the follow-up to their 2011 article on the improved survival of metastatic castration-resistant prostate cancer treated with abiraterone. The study enrolled 1195 patients at 147 sites in 13 countries. The patients were included in the study if they had metastatic castration-resistant prostate cancer progressing after docetaxel. Patients were randomly assigned in a 2 to 1 ratio to receive abiraterone acetate (1000 mg orally once daily) plus prednisone (5 mg orally twice daily) or placebo plus prednisone. Overall survival was the primary endpoint of the study. Of the 1195 eligible patients, 797 were assigned to the abiraterone arm and 398 to the placebo arm. At median follow-up of 20.2 months, the median survival for the abiraterone group was longer than the placebo, that is, 15.8 months versus 11.2 months (p < .0001). Side effects were mild and generally mineralocorticoid-related such as hypertension, hypokalemia, and fluid retention. One of the major advantages of abiraterone is that it can be administered orally in the outpatient setting. As noted in the accompanying editorial, 4 this study most likely will result in the preferred use of abiraterone before the institution of docetaxel in the near future. In addition, other androgen inhibitors (orteronel), androgen receptor inhibitors (enzalutamide, ARN-509), and agents with both of these mechanisms of activity (galeterone) are undergoing clinical assessment.
Enzalutamide, unlike abiraterone, inhibits androgen receptor signaling by blocking the binding of androgens without stimulation of the receptor. It is now recognized that this androgen receptor plays an important role in metastatic castrationresistant prostate cancer. Androgens can still stimulate tumor growth, through multiple mechanisms, and are an excellent target for these receptor-inhibiting drugs. Scher et al 5 just reported the results of a Phase 3, double-blind, and placebo-controlled trial of enzalutamide in 1199 men with castration-resistant prostate cancer following chemotherapy. In a 2 to 1 ratio, 800 men received enzalutamide (160 mg orally once daily) or 399 were given a placebo. The median overall survival was 18.4 months in the enzalutamide group versus 13.6 months in the placebo group. Fatigue, diarrhea, and hot flashes were higher in the enzalutamide group and 5 (.6%) patients experienced a seizure. As noted by the investigators, enzalutamide is given once daily without prednisone and significantly prolongs survival in men with metastatic castration-resistant prostate cancer after chemotherapy.
The following is a brief summary of the Phase 3 trials of the newer treatment options for metastatic castrationresistant prostate cancer (modified from reference 6): The better identification and understanding that prostate cancer is never really hormonal resistant has significantly restructured thinking about the treatment of this disease. The use of drugs to further suppress androgen production and block androgen receptors provides heightened optimism for treatment of metastatic cancer of the prostate disease.
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